SB treatment, which acts through inhibition of both class I and II HDACs, was shown to improve memory in APP/PS1 mice (Govindarajan et al., 2013; Kilgore et al., 2010), to reduce amyloid burden in 5xFAD mouse model (Fernando et al., 2020), and to restore learning behavior and enhance neurogenesis in PS1/2 cDKO mice, an Aβ‐independent mouse model of AD (Cao et al., 2018). This evidence concerns the gene APP and amyloidosis.